Centile Bioscience Inc. — SEC Form D Filing
Centile Bioscience Inc. filed an SEC Form D on April 16, 2026, reporting $3.05M raised in Healthcare Technology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- April 16, 2026
- Amount reported
- $3.05M
- Round stage
- Seed
- Industry
- Healthcare Technology
- Website
- https://centilebio.com/
What the company does
Securities: Equity, Convertible securities. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Clinicians face challenges in effectively utilizing the vast amount of data from brain imaging scans, which often remain unexamined, leading to poorer patient outcomes.
Solution
Centile Bioscience uses data science and algorithmic intelligence to analyze brain scans and develop actionable insights, enhancing diagnostic accuracy and patient care.
Why now
The demand for effective brain disease diagnostics is escalating due to an aging population and a declining workforce of radiologists.
Verdict
Investors said yes because Centile Bioscience presented a clear solution to the challenge of underutilized brain imaging data, not because competitors were absent. They were betting on the urgent demand for enhanced diagnostic capabilities amid a shrinking number of qualified radiologists, which implies a potential market shift towards automated solutions. However, the limited upside stems from the still-maturing nature of AI in diagnostics, which may constrain durability and widespread adoption.
Source: SEC EDGAR Form D filing